Scott Howe, MD
Urology · Kearney, NENPI 1225065535
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 145 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $628 and has fallen 54.6% since, to $285 in 2025. That places this record below the midpoint for urology clinicians in NE, where the typical reported total is $2,774.
Across 145 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$574
- Astellas Pharma US Inc$387
- KARL Storz Endoscopy-america$230
- Pfizer$226
- Teleflex LLC$192
- Bayer$160
- plus $918 from 26 others
What the payments were for
- Food & beverage$2,63298%
- Education$542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 37 | $574 |
| Astellas Pharma US Inc | 30 | $387 |
| KARL Storz Endoscopy-america | 4 | $230 |
| Pfizer | 12 | $226 |
| Teleflex LLC | 6 | $192 |
| Bayer | 9 | $160 |
| KARL Storz Lithotripsy-america | 1 | $98 |
| Novartis | 4 | $94 |
| Johnson & Johnson | 5 | $85 |
| Endo Pharmaceuticals Inc. | 5 | $70 |
| Verity Pharmaceuticals Inc. | 3 | $61 |
| Merck | 3 | $61 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $45 |
| Urogen Pharma, Inc. | 2 | $39 |
| Dendreon Pharmaceuticals LLC | 2 | $33 |
| Neotract Inc. | 1 | $31 |
| Olympus America Inc. | 2 | $29 |
| AstraZeneca | 2 | $27 |
| Innovation Technologies Inc | 1 | $25 |
| Coloplast | 2 | $24 |
| Calyxo, Inc. | 1 | $22 |
| Axonics, Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 1 | $19 |
| Tolmar, Inc. | 1 | $19 |
| 180 Medical, Inc. | 1 | $17 |
| Foundation Medicine, Inc. | 1 | $16 |
| Janssen Scientific Affairs, LLC | 1 | $16 |
| Blue Earth Diagnostics | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Myovant Sciences Inc. | 1 | $12 |
| SRS Medical Systems, Inc. | 1 | $11 |
How this compares
$2,686 in reported general payments places this provider in the 45th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 26 | $402,367 |
| Abiraterone Acetate | 37 | $84,968 |
| MyrbetriqMirabegron | 129 | $65,533 |
| GemtesaVibegron | 24 | $13,375 |
| Dutasteride | 231 | $5,834 |
| RenacidinCitric Ac/Gluconolact/Mag Carb | 27 | $5,210 |
| Tamsulosin Hcl | 242 | $3,127 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 26 | $2,336 |
| Solifenacin Succinate | 68 | $1,911 |
| Methenamine Hippurate | 40 | $1,867 |
| Testosterone | 13 | $1,826 |
| Finasteride | 81 | $742 |
| Oxybutynin Chloride ErOxybutynin Chloride | 17 | $520 |
| Megestrol Acetate | 34 | $402 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $387 | $467,900155 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $16 | $84,96837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 79 urology providers in Nebraska.
Other urology in Kearney
- Garrett PohlmanKearney$123K
- Laroy WilliamsKearney$6K
- John BishayOmaha$138K
- Rebecca McCreryOmaha$71K
- Judson DaviesOmaha$67K
- Stefanie BolteOmaha$59K
- Antonio BeltranLincoln$51K
- Michael FeloneyOmaha$29K
- Ansar KhanFremont$15K
- Don HensleeFairbury$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.